EDMONTON, Feb. 7 /CNW/ - BioMS Medical Corp. (TSX: MS), a leading
developer in the treatment of multiple sclerosis (MS), today announced that
following the third meeting of the independent Data Safety Monitoring Board
(DSMB), the Company has received a recommendation to continue its pivotal
phase II/III clinical trial for MBP8298 for the treatment of secondary
progressive multiple sclerosis.
